Psychiatr News June 2, 2006
Volume 41, Number 11, page 6
© 2006 American Psychiatric Association
Combined Treatment Reduces Drinking Problems
Eve Bender
Treatments for alcohol dependence, including monitoring of patients'
functioning and medication adherence, along with a behavioral intervention,
may reduce problem drinking.
A multisite clinical trial of treatments for alcohol dependence shows that
when combined with medical management, the medication naltrexone is as
effective as up to 20 sessions of a type of behavioral therapy in terms of
reducing drinking.
Findings from the Combined Pharmacotherapies and Behavioral Interventions
(COMBINE) study also showed that the medication acamprosate had no effect on
reducing drinking and no added benefit when combined with naltrexone.
The findings appear in the May 3 Journal of the American Medical
Association.
Naltrexone is an opiate antagonist. Although it was originally used to
treat opioid dependence, the Food and Drug Administration also approved it for
alcoholism.
Acamprosate is a glutamate receptor modulator and is thought to reduce the
discomfort associated with protracted abstinence from alcohol.
Roger Weiss, M.D., principal investigator for the McLean Hospital study
site, told Psychiatric News that he found the results encouraging and
said he thought it would be feasible to treat alcohol-dependent patients with
naltrexone and/or combined behavioral therapy with medical management in both
primary care offices and mental health treatment centers.
To assess the effect of a number of treatments on alcohol addiction,
researchers at 11 treatment centers across the United States gathered data on
1,383 recently abstinent alcohol-dependent subjects recruited through
advertisements or referrals.
The more than 1,000 subjects were randomly placed in one of nine treatment
groups (of about 150 patients each) for 16 weeks of outpatient treatment:
patients in eight of the groups received medical management from a clinician
who reviewed patients' diagnosis of alcohol dependence with them, recommended
abstinence from alcohol, and discussed patients' overall functioning and
medication adherence.
Patients in four of the groups also received up to 20 50-minute sessions of
a combined behavioral intervention (CBI), which integrated motivational
interviewing, aspects of cognitive-behavioral therapy, and encouragement to
participate in 12-step groups.
Motivational interviewing was described as a nonconfrontational style of
interviewing patients that involved empathy, helped patients to reflect on
their choices, and assessed the patient's strengths.
Four groups of patients also received one of the following: naltrexone (100
mg a day), acamprosate (3 g a day), a combination of the two drugs, or
placebo. The placebo group received CBI alone.
Researchers assessed the patients at several time points during the 16-week
treatment trial and up to a year after the treatment trial to determine the
percentage of days abstinent from alcohol and the time to the first
heavy-drinking day (defined as four or more drinks a day for women and five or
more for men).
They also assessed the odds of good clinical outcome, defined as abstinence
or moderate drinking with no alcohol-related problems.
During the treatment period, patients receiving naltrexone plus medical
management (n=302), CBI plus medical management and placebo (n=305), or both
naltrexone and CBI plus medical management (n=309) had a higher percentage of
days abstinent (80.6 percent, 79.2 percent, and 77.1 percent, respectively)
than the 75 percent of days abstinent in groups receiving placebos and medical
management only (n=305).
The interaction of naltrexone and CBI was statistically significant at
p=.009, according to the study.
Naltrexone plus medical management was also found to reduce the risk of
having a heavy-drinking day over the study period (p=.02).
The study also found that those receiving CBI without medication or medical
management (n=157) had a lower percentage of days abstinent from alcohol (66.6
percent) than did those receiving placebo plus medical management alone
(n=153) or placebo plus medical management and CBI (n=156) (73.8 percent and
79.8 percent, respectively).
One year after treatment, there were similar differences between the
groups, but none was statistically significant. Moreover, acamprosate showed
no effect on drinking, either alone or with any combination of naltrexone,
CBI, or both.
Weiss noted that while CBI is best conducted by a specialist with training
in alcohol dependence treatment, medical management can be conducted in the
primary care setting by a wide range of health clinicians.
He said that researchers are continuing to analyze data from the COMBINE
study to identify predictors of good clinical outcomes in regard to recovery
from alcohol dependence.
The study was funded by the National Institute on Alcohol Abuse and
Alcoholism.
An abstract of "Combined Pharmacotherapies and Behavioral
Interventions for Alcohol Dependence: The COMBINE Study: A Randomized
Controlled Trial" is posted at
<http://jama.ama-assn.org/cgi/content/abstract/295/17/2003>.
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
| 
